News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,484 Results
Type
Article (44197)
Company Profile (308)
Press Release (680979)
Multimedia
Podcasts (92)
Webinars (12)
Section
Business (212338)
Career Advice (2183)
Deals (37095)
Drug Delivery (115)
Drug Development (84219)
Employer Resources (177)
FDA (16719)
Job Trends (15581)
News (359943)
Policy (34442)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (5)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2632)
Accelerated approval (5)
Adcomms (26)
Allergies (88)
Alliances (52065)
ALS (93)
Alzheimer's disease (1407)
Antibody-drug conjugate (ADC) (141)
Approvals (16706)
Artificial intelligence (270)
Autoimmune disease (26)
Automation (16)
Bankruptcy (377)
Best Places to Work (11842)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (193)
Bladder cancer (67)
Brain cancer (28)
Breast cancer (278)
Cancer (2246)
Cardiovascular disease (188)
Career advice (1818)
Career pathing (33)
CAR-T (153)
Cell therapy (424)
Cervical cancer (19)
Clinical research (68398)
Collaboration (860)
Compensation (534)
Complete response letters (28)
COVID-19 (2681)
CRISPR (43)
C-suite (242)
Cystic fibrosis (103)
Data (2121)
Decentralized trials (2)
Denatured (29)
Depression (46)
Diabetes (278)
Diagnostics (6473)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (125)
Drug pricing (119)
Drug shortages (31)
Duchenne muscular dystrophy (95)
Earnings (88590)
Editorial (39)
Employer branding (21)
Employer resources (152)
Events (116217)
Executive appointments (729)
FDA (17960)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (764)
Gene editing (110)
Generative AI (24)
Gene therapy (311)
GLP-1 (792)
Government (4609)
Grass and pollen (5)
Guidances (52)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (131)
Indications (29)
Infectious disease (2834)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (94)
Interviews (340)
IPO (16941)
IRA (48)
Job creations (4162)
Job search strategy (1555)
Kidney cancer (11)
Labor market (38)
Layoffs (503)
Leadership (21)
Legal (8531)
Liver cancer (74)
Lung cancer (322)
Lymphoma (150)
Machine learning (6)
Management (61)
Manufacturing (321)
MASH (70)
Medical device (13497)
Medtech (13502)
Mergers & acquisitions (20686)
Metabolic disorders (740)
Multiple sclerosis (82)
NASH (20)
Neurodegenerative disease (96)
Neuropsychiatric disorders (33)
Neuroscience (1961)
NextGen: Class of 2025 (6726)
Non-profit (4553)
Northern California (2616)
Now hiring (39)
Obesity (405)
Opinion (248)
Ovarian cancer (75)
Pain (92)
Pancreatic cancer (82)
Parkinson's disease (154)
Partnered (21)
Patents (238)
Patient recruitment (106)
Peanut (50)
People (59762)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21312)
Phase II (30047)
Phase III (22511)
Pipeline (1168)
Policy (157)
Postmarket research (2685)
Preclinical (8975)
Press Release (68)
Prostate cancer (102)
Psychedelics (31)
Radiopharmaceuticals (254)
Rare diseases (402)
Real estate (6366)
Recruiting (67)
Regulatory (23451)
Reports (46)
Research institute (2392)
Resumes & cover letters (370)
Rett syndrome (4)
RNA editing (4)
RSV (48)
Schizophrenia (75)
Series A (132)
Series B (86)
Service/supplier (14)
Sickle cell disease (55)
Southern California (2246)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3793)
State (2)
Stomach cancer (15)
Supply chain (73)
Tariffs (38)
The Weekly (61)
United States (22864)
Vaccines (714)
Venture capitalists (41)
Weight loss (286)
Women's health (36)
Worklife (16)
Date
Today (40)
Last 7 days (660)
Last 30 days (2441)
Last 365 days (33612)
2025 (10174)
2024 (36148)
2023 (40930)
2022 (52113)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33570)
2016 (33170)
2015 (39008)
2014 (32961)
2013 (28077)
2012 (30166)
2011 (30871)
2010 (28889)
Location
Africa (809)
Alabama (52)
Alaska (7)
Arizona (239)
Arkansas (14)
Asia (41677)
Australia (6621)
California (5991)
Canada (1989)
China (529)
Colorado (264)
Connecticut (267)
Delaware (144)
Europe (89344)
Florida (896)
Georgia (202)
Idaho (57)
Illinois (538)
India (26)
Indiana (320)
Iowa (11)
Japan (163)
Kansas (102)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (891)
Massachusetts (4507)
Michigan (218)
Minnesota (388)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (61)
New Hampshire (62)
New Jersey (1710)
New Mexico (31)
New York (1702)
North Carolina (1005)
North Dakota (7)
Northern California (2616)
Ohio (202)
Oklahoma (14)
Oregon (40)
Pennsylvania (1348)
Puerto Rico (12)
Rhode Island (32)
South America (1184)
South Carolina (22)
South Dakota (1)
Southern California (2246)
Tennessee (102)
Texas (895)
Utah (181)
Virginia (150)
Washington D.C. (62)
Washington State (554)
West Virginia (3)
Wisconsin (54)
725,484 Results for "cocrystal pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
April 16, 2025
·
1 min read
Press Releases
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
April 25, 2025
·
6 min read
Press Releases
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
April 1, 2025
·
12 min read
Press Releases
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
March 6, 2025
·
1 min read
Business
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
May 13, 2024
·
13 min read
Press Releases
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
April 11, 2025
·
6 min read
Business
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
March 28, 2024
·
14 min read
Press Releases
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
December 31, 2024
·
6 min read
Drug Development
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
May 1, 2024
·
5 min read
Press Releases
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
January 9, 2025
·
6 min read
1 of 72,549
Next
